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ABSTRACT 
Currently, a variety of ophthalmic products illustrate low bioavailability after topical administration because of anatomical  and physiological 
barriers of eye. Ketorolac tromethamine (KT) is a BCS class I, potent anti-inflammatory drug. The rationale of present work was to design and 
develop KT nanosuspension loaded in situ gel with sustained effect and greater permeability for ocular drug delivery through increased ocular 
residence time of drug. KT nanosuspension loaded in situ gel was designed by using 32factorial design. Polymers and surfactant were optimized 
through trial batches exhibiting better drug content (%), In Vitro trans-corneal permeation (%) and corneal hydration (%).Optimized 
formulation was evaluated for clarity, pH, gelling capacity, rheological behavior, drug content (%), Ex-vivo trans-corneal permeation, corneal 
hydration, HET CAM assay and physical stability. The resultant formulations revealed optimum viscosity, pH and drug content; as well as higher 
trans-corneal permeability when compared to the marketed eye drop. Optimized formulation was found as nonirritant to eye with susta ined 
effect and good stability. So, current system can be considered as an efficient ocular drug delivery system for the treatment of postoperative 
inflammation, which would improve patient compliance and ocular bioavailability. 
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1. INTRODUCTION 
Ketorolac tromethamine (KT) is a BCS class I drug having 
potent anti-inflammatory activity. Chemically it is a 
pyrrolizine carboxylic acid; NSAID used for the treatment of 
post-operative eye inflammation and conjunctivitis1-2. Being 
water soluble agent; to formulate nanosystem is quite 
difficult by entrapment in polymeric vehicle3. Generally the 
basic problems for topical application in the treatment of 
ocular infection is drug loss from pre-corneal surface, 
conjunctival uptake due to poor bioavailability and rapid 
drainage through naso-lacrimal areas4-5. However, short pre-
corneal contact time combined with corneal impermeability 
result in low bioavailability, and frequent dosing is usually 
needed6. Nanosuspension by nanoprecipitation is the novel 
drug delivery approach for sustaining the drug in its 
crystalline state7-9. Selection of polymers and stabilizers are 
very essential in the development of nanosuspensions to 
avoid particle aggregation, and crystal growth10-11. Design of 
experiment has proven effective optimization of 
formulations10-11. In present investigation; formulation was 
optimized by using 32 factorial design. Hence, based on 
above challenge, KT nanosuspension loaded in situ gel 
increases ocular bioavailability, and residence time on the 
corneal surface. The rationale of present work was to design 
and develop KT nanosuspension loaded in situ gel with 
sustained effect and greater permeability for challenging 
ocular drug delivery. 
 
 
Figure 1: Chemical structure of ketorolac tromethamine 
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2. MATERIALS AND METHODS 
2.1. Materials 
Ketorolac tromethamine (KT) gifted from Zhejiang 
Medicines and Health Products Imports & Exports Co. Ltd. 
China, was used as a model drug in the study. Eudragit RL-
100 was received as a gift sample from Evonik Industries, 
Mumbai. Carbopol 934, sodium alginate and poloxamer 188 
were procured from Sigma Aldrich. All other chemicals and 
reagents were of analytical grade. Double distilled water was 
used throughout the investigation. 
2.2.  Methods 
2.2.1. Selection and preliminary optimization of gelling agent 
and preservatives by formulation of trial batches 
Initially, trial batches were formulated using two different 
gelling agents (sodium alginate and carbopol 934) at 
different concentrations. Benzalkonium chloride was used as 
a preservative at various concentrations. Freeze dried 
powder of optimized KT loaded nanosuspension was 
dispersed into in situ gelling system of different gelling 
agents, and then subjected for determination of trans-
corneal permeation and corneal hydration study. Based on 
results, gelling agent and preservative were optimized for 
design of formulations. 
2.2.2. Experimental Design 
Initially screening studies were performed to test the effect 
of process parameters and formulation parameters to 
fabricate stable KT nanosuspension loaded in situ gel. The 
concentration of sodium alginate (% w/w) and 
concentration of benzalkonium chloride (% w/w) were 
acknowledged as significant formulation parameters (Table 
1). Design of experiment was used thoroughly to evaluate 
and optimize the selected formulation parameters at three 
levels (-1, 0, +1) using 32 factorial design to find out their 
effects on critical quality attributes of KT nanosuspension 
loaded in situ gel. 
2.2.3. Preparation of KT nanosuspension loaded in situ gel 
Nanoprecipitation followed by probe sonication technique 
was used to prepare KT loaded nanosuspensions. Drug and 
polymers were co-dissolved in 10 ml organic solution 
(methanol: acetone in 1:1 ratio). The solution was slowly 
injected drop wise in 100 ml of distilled water containing 
surfactant using high speed homogenizer at 2500 rpm. 
Organic solvent was evaporated completely. To the resulting 
uniform nanosuspension, probe sonication was used at 20-
25 kHz for 5 min. The optimized formulation KT6 was 
lyophilized with mannitol as cryoprotectant by lyophilizer 
(Christ, Alpha, 12LD PLUS). The freeze dried product was 
kept in air tight container. 
Accurately weighed sodium alginate was dissolved in hot 
distilled water, cooled at room temperature and lyophilized 
powder of optimized KT nanosuspension was dispersed into 
it. To above system, benzalkonium chloride was added as a 
preservative at the end. HPMC E15 (1 %) is used as co-
polymer using a magnetic stirrer to dissolve polymer 
completely. Sodium chloride (0.9 %) was added as 
isotonicity adjuster. The pH of the solution was adjusted to 
6.5 using 0.1 N NaOH/0.1 N HCl.  
2.2.4. Evaluation of optimized KT nanosuspension loaded in 
situ gel 
2.2.4.1. Test for Clarity and pH 
Clarity was observed for the presence of any particular 
matter visually. The pH of formulations were determined, 
using a calibrated pH meter (Digital Systronic, Mumbai, 
India).The average reading was recorded (n=3). 
2.2.4.2. Gelling capacity determination 
Gelling capacity of the formulation was determined by 
insertion of a drop of the formulation in a vial having 2 ml of 
fresh simulated tear fluid, and visually observed. The time 
taken for gelling was noted12-14. 
2.2.4.3. Rheological study 
The viscosity of the gels was determined on Brookfield 
Viscometer (Brookfield Ametek) by using L1 spindle at 100 
rpm. 
2.2.4.4. Drug content (%) determination 
Drug content was determined by taking 1 ml gel in 50 ml 
volumetric flask. It was dissolved in distilled water properly 
and the final volume was made up to 50 ml with it. After 
appropriate dilution, the absorbance of prepared solution 
was measured at 322 nm by using UV spectrophotometer 
(UV-1800, Shimadzu, Japan) and % drug content in the 
formulation was calculated. 
2.2.4.5. Ex-vivo trans-corneal permeation and corneal 
hydration study 
The corneal area available for diffusion was 0.5 cm2 which 
was placed between donor and receptor compartments of 
modified Franz diffusion cell with epithelial surface faced 
the donor compartment. Receptor compartment was filled 
with 10 ml fresh; simulated tear fluid (pH 7.4) and all air 
bubbles were removed from the compartment. An aliquot (1 
ml) of prepared KT nanosuspension loaded in situ gel was 
placed on the cornea and the opening of the donor cell was 
sealed with a glass cover slip; receptor fluid was kept at 37 
°C with constant stirring using a Teflon-coated magnetic stir 
bead. Permeation study was continued for 120 minutes, and 
samples were withdrawn from receptor and analyzed for 
ketorolac tromethamine content by measuring absorbance 
at 322 nm using UV spectrophotometer (UV-1800, 
Shimadzu, Japan).  Results were expressed as percentage 
permeation or In vitro ocular availability. Marketed 
formulation of KT was used for comparative analysis. The 
permeation (%) or In vitro ocular availability was calculated 
as follows15-16. 
Permeation (%) = {Qty. of drug permeated/Initial Qty.} × 
100 
In brief, at the end of the experiment, the scleral tissue was 
removed from cornea; its epithelial surface was wiped with 
filter paper and weighed (Initial weight). The cornea was 
then soaked in 1ml of methanol, dried overnight at 90 °C, 
and reweighed (Final weight). From the difference in weight, 
corneal hydration (%) was calculated as follows15-16. 
Corneal hydration = {(Initial weight-Final weight)/Initial 
weight} × 100 
2.2.4.6.  HET-CAM assay 
HET-CAM assay was completed following ICCVAM 
recommendations (Appendix G, November 2006)17-19. Clean 
and fertile chicken eggs weighing 40-50 gm were purchased 
from commercial sources. Those eggs were candled to detect 
the viability and development of embryo before use. 
Nonviable or defective eggs were discarded. Finally, six eggs 
(after 9th day of incubation) per group were used in the 
study to evaluate the potential of a test substance to produce 
ocular irritation using their chorio-allantoic membrane 
(CAM) 17-19. Care should be taken while removing the 
eggshell to ensure that the inner membrane was not injured. 
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The NaCl (0.9 %) solution was applied in each experiment to 
provide a baseline for the assay. Negative Control (0.3 ml of 
1 % SDS + 0.3 ml of 0.1 N NaOH) and 0.3 ml of test 
formulation was applied on the CAM of treatment group 
ensuring that at least 50 % of the CAM surface area was 
covered. Marketed formulation (0.3 ml, Acular LS) directly 
applied on the CAM of standard group. Effects were checked 
for blood vessel lysis, hemorrhage and coagulation. 
Accordingly, combined score was derived to classify the 
irritancy level of the test substance. The reactions on the 
CAM were observed over a period of 5 min (0.5 min, 2 min & 
5 min) and time for the appearance of each of the noted 
endpoints should be recorded, in seconds17-19. 
2.2.4.7. Accelerated stability studies  
Optimized sterile gel formulation was evaluated for its 
stability. Formulation was filled in glass vials, closed with 
rubber closures and sealed with an aluminum caps. It was 
kept in the stability chamber (Remi) at 40 ± 2°C temperature 
and 75 ± 5 % RH for one month20. Samples were withdrawn 
at specific time intervals and analyzed for visual appearance, 
drug content, pH, gelling capacity and trans-corneal 
permeation. 
2.2.4.8. Statistical analysis 
Statistically data were analyzed using Microsoft Excel 2007 
and Design Expert 7.0.0 software. The results were 
documented as mean ± SD (n=3). 
3. RESULTS AND DISCUSSION 
3.1.  Selection and preliminary optimization of gelling agent 
and preservatives by formulation of trial batches 
Sodium alginate in the range of 0.5 % w/w to 1.5 % w/w 
was selected as mucoadhesive gelling agent based on 
results21-22. Benzalkonium chloride in the range of 0.05 % 
w/w to 0.1 % w/w was optimized as a preservative. All 
formulations in that range showed trans-corneal permeation 
in between 5.1 ± 0.04 % to 9.3 ± 0.17 %. Corneal hydration 
of all formulations were found in between 77.05 ± 0.06% to 
79.77 ± 0.08 %; depicting normal range without damage to 
the corneal tissue. The concentration range was optimized 
based on highest % permeation and normal value of corneal 
hydration. 
3.2. Experimental Design 
Regression analysis of data acquired from the experimental 
runs generated following equations in which F ratios were 
statistically significant (p< 0.05) with Adj-R2 value in the 
range of 0.9-1 (Table 2) and with a statistically non-
significant lack of  fit values (p> 0.05).  
 
Table 1: Preparation of KT nanosuspension loaded in situ gel using 32 factorial design 
Formulation 
Code 
Independent Variables Dependent Variables 
Formulation Variable Y1 Y2 Y3 
X1 
Conc. of 
Sodium 
Alginate 
(% w/w) 
X2 
Conc. of 
Benzalkonium 
Chloride 
(% w/w) 
Drug Content (%) 
Trans-corneal 
Permeation 
(%) 
Corneal 
Hydration (%) 
KTNG1   1 0.5   1 0.5 76.18 ± 1.17 2.9 ± 0.2 76.81 ± 0.96 
KTNG2 0 1   1 0.5 79.11 ± 1.09 3.1 ± 0.2 77.19 ± 0.87 
KTNG3 +1 1.5   1 0.5 83.25 ± 1.31 3.6 ± 0.1 78.41 ± 0.81 
KTNG4   1 0.5 0 0.75 77.12 ± 0.97 3.0 ± 0.3 76.91 ± 0.93 
KTNG5 0 1 0 0.75 79.91 ± 1.18 3.3 ± 0.2 77.12 ± 1.07 
KTNG6 +1 1.5 0 0.75 84.19 ± 0.83 3.7 ± 0.1 78.34 ± 1.05 
KTNG7   1 0.5 +1 1 76.32 ± 0.98 2.8 ± 0.3 76.55 ± 0.77 
KTNG8 0 1 +1 1 78.47 ± 0.99 3.1 ± 0.2 77.07 ± 1.12 
KTNG9 +1 1.5 +1 1 83.92 ± 1.28 3.6 ± 0.2 78.41 ± 0.81 
Where +1 is higher level, –1 is lower level and 0 is mid level for the independent variable and all values are expressed as mean ± 
SD (n = 3). 
 
These model equations fitted the data well. A positive sign indicates a synergistic effect, while negative sign indicates an 
antagonistic effect21-23, 27. 
Drug Content (%) = 79.74 + (3.62 × X1) + (0.028 × X2) + (0.13 × X1.X2) + (1 × X12) – (0.86 × X22) (Quadratic model)……… (1) 
Trans-corneal Permeation (%) = 3.27 + (0.37 × X1) – (0.017 × X2) + (0.025 × X1.X2) + (1 × X12) – (0.15 × X22) (Quadratic 
model)……… (2) 
Corneal Hydration (%) = 77.16 + (0.82 × X1) – (0.063 × X2) + (0.065 × X1.X2) + (0.44 × X12) – (0.05 × X22) (Quadratic model)……… 
(3) 
Where X1 and X2 are concentration of sodium alginate (% w/w) and concentration of benzalkonium chloride (% w/w) 
respectively. 
Equation (1) represents that, increase in concentration of both sodium alginate and benzalkonium chloride increases % drug 
content. According to equations (2) and (3), concentration of sodium alginate is directly proportional and concentration of 
benzalkonium chloride is inversely proportional to % trans-corneal Permeation and % corneal Hydration respectively. 
Response surface plots displayed in figure 2 clearly supports the results. 
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Table 2: Results of statistical analysis of the experimental design 
Responses 
Sources 
Model p value Adj-R2 Lack of fit test p value 
Drug Content (%) 0.0014 0.9371 0.3791 
Trans-corneal Permeation (%) 0.0011 0.9558 0.7746 
Corneal Hydration (%) 0.0022 0.9119 0.3272 
 
 
Figure 2: Response surface plots showing the effect of conc. of sodium alginate (% w/w) and conc. of benzalkonium chloride 
(% w/w) on (A) Drug content, (B) Trans-corneal permeation and (C) Corneal hydration  
The desirability function was evaluated by Design-Expert software to obtain the optimized KT nanosuspension loaded in situ 
gel. The model verification results are displayed in table 3; that comparing observed and predicted values of drug content, 
trans-corneal permeation and corneal hydration by using model equations. 
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Table 3: Comparison of observed and predicted values of responses of optimized KT nanosuspension loaded in situ gel 
Factors Predicted value Observed value* 
Conc. of 
Sodium 
Alginate 
(% w/w) 
Conc. of 
Benzalkonium 
Chloride 
(% w/w) 
Drug 
Content (%) 
Trans-
corneal 
Permeati
on (%) 
Corneal 
Hydration 
(%) 
Drug Content 
(%) 
Trans-
corneal 
Permeati
on (%) 
Corneal 
Hydration 
(%) 
1.5 0.75 84.31 3.73 78.41 84.19 ± 0.83 3.7 ± 0.1 
78.34 ± 
1.05 
* All values are mean ± SD (n=3). 
3.3.  Evaluation of optimized KT nanosuspension loaded in situ gel  
3.3.1.  Test for Clarity and pH 
All formulations found as clear in appearance. The pH values for all the formulations are within adequate range 6.51- 6.53 and 
hence there will be no irritation occurs upon administration in the eye. 
Table 4: Evaluation parameters of optimized KT nanosuspension loaded in situ gel 
Formulation 
Code 
Appearance Clarity pH 
Drug Content 
(%) 
Gelling 
Capacity 
Viscosity 
(cp) 
KTNG1 Transparent Clear 6.51 ± 0.01 76.18 ± 1.17 ++ 618.3 
KTNG2 Transparent Clear 6.51 ± 0.01 79.11 ± 1.09 ++ 1177.9 
KTNG3 Transparent Clear 6.50 ± 0.02 83.25 ± 1.31 ++ 1873.2 
KTNG4 Transparent Clear 6.53 ± 0.01 77.12 ± 0.97 ++ 633.7 
KTNG5 Transparent Clear 6.51 ± 0.00 79.91 ± 1.18 ++ 1187.3 
KTNG6 Transparent Clear 6.49 ± 0.01 84.19 ± 0.83 ++ 1789.5 
KTNG7 Transparent Clear 6.49 ± 0.01 76.32 ± 0.98 ++ 627.9 
KTNG8 Transparent Clear 6.52 ± 0.01 78.47 ± 0.99 ++ 1203.5 
KTNG9 Transparent Clear 6.52 ± 0.02 83.92 ± 1.28 ++ 1810.6 
++ Immediate gelation remains for few hours. 
 
3.3.2. Gelling capacity determination 
The gelling capacity data of all formulations (Table 4) 
depicted immediate gelation that existed for 2 to 3 hr. 
3.3.3. Rheological study 
Rheological evaluation of all the formulations exhibited 
moderate viscosity in the range of 618.3 to 1873.2 cp. It is 
favorable to form in situ gel with its integrity26-28, 30.  
3.3.4. Drug content (%) determination 
The drug content values for all the formulations were found 
within the range of 76.18 to 84.19 %. Optimized batch 
KTNG6 showed 84.19 % drug content. 
3.3.5.  Ex-vivo trans-corneal permeation and corneal 
hydration study 
The ex-vivo trans-corneal permeation after 2 hr of all gel 
formulations were depicted in table 1 (2.8 to 3.7 %). 
Marketed KT formulation showed 73.23 % trans-corneal 
permeation for the same time. Such large difference might 
be due to the slow release of drug from nanoparticles 
incorporated in gelling matrix. Corneal hydration values of 
all formulations were observed in between 76.55 to 78.41%. 
It was indicating normal corneal hydration without any 
damage to the corneal tissue. 
3.3.6.  HET-CAM assay 
Irritancy Potential of optimized formulation was evaluated 
by using Hen’s Egg Test Chorio-Allantoic Membrane Assay 
(HET-CAM Assay) and the time for the appearance of each of 
the observed endpoints on the CAM over a period of 5 min 
(0.5 min, 2 min & 5 min) were recorded, as in table 5. Effects 
observed were displayed in figure 3.The test sample was 
observed as non irritant when compared to negative control.
 
Table 5: HET-CAM Test Scores 
 
Egg No. 
0.9 % NaCl (Control) 
1% SDS + 0.1 N NaOH 
(Negative Control) 
Test Sample (Test 
Group) 
Acular LS (Standard 
Group) 
0.5 
min 
2 min 5 min 
0.5 
min 
2 min 5 min 
0.5 
min 
2 min 5 min 
0.5 
min 
2 min 5 min 
Egg 1 0 0 0 5 5 5 0 0 0 0 0 0 
Egg 2 0 0 0 8 6 5 0 0 0 0 0 0 
Egg 3 0 0 0 7 5 3 0 0 0 0 0 0 
Egg 4 0 0 0 5 6 5 0 0 0 0 0 0 
Egg 5 0 0 0 9 5 5 0 0 0 0 0 0 
Egg 6 0 0 0 7 5 3 0 0 0 0 0 0 
Mean (Time in 
Second) 
0 0 0 6.83 5.33 4.33 0 0 0 0 0 0 
 
Jadhav et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):203-209  
ISSN: 2250-1177                                                                                  [208]                                                                                 CODEN (USA): JDDTAO 
 
Figure 3: Effects observed; A) Positive control, B) Negative 
control, C) Test Solution & D) Acular LS during HET-CAM 
assay 
3.3.7. Accelerated stability studies 
During accelerated stability studies; optimized sample was 
analyzed periodically for visual appearance, clarity, pH and 
gelation. No significant changes were observed indicating 
stable formulation. Trans-corneal permeation profile was 
found as almost similar as that of its initial value. 
4. CONCLUSIONS 
In the present investigation, sustained release ketorolac 
tromethamine nanosuspension loaded in situ gel forming 
ophthalmic solutions were prepared using sodium alginate 
and HPMC E15. Sodium alginate, a mucoadhesive polymer, 
which gets converted to gel effectively in the presence of 
divalent-cations (Ca++) present in the lachrymal fluid. 
Benzalkonium chloride was proven the suitable preservative 
for the preparations. During process; 32 factorial design was 
used to optimize the best formulation. All resultant 
formulations exhibited optimal viscosity, pH, drug content, 
corneal hydration and nonirritant nature. Optimized gel 
demonstrated excellent trans-corneal permeability and 
physical stability. It can be concluded that, ketorolac 
tromethamine nanosuspension loaded in situ gel will be the 
efficient ocular drug delivery system for the treatment of 
postoperative inflammation through improved patient 
compliance and ocular bioavailability. 
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